Pathology

The College of American Pathologists Hosts 2021 Annual Meeting: September 25-28

Thursday, September 23, 2021 - 8:54pm

The College of American Pathologists (CAP) will host its CAP21 Annual Meeting with timely and informative educational sessions from Sat., Sept. 25 through Tues., Sept. 28 at the Hyatt Regency Chicago.

Key Points: 
  • The College of American Pathologists (CAP) will host its CAP21 Annual Meeting with timely and informative educational sessions from Sat., Sept. 25 through Tues., Sept. 28 at the Hyatt Regency Chicago.
  • Pathologists have been resilient as 2021 continues to be an extraordinary and remarkable year in our profession, says CAP President Emily E. Volk, MD, FCAP.
  • Pathologists oversee and provide laboratory testing and diagnose viruses, chronic diseases, cancers and other health conditions.
  • For more information, visit yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care.

Kindbody Appoints Dean Morbeck, Ph.D., as First Chief Scientific Officer

Thursday, September 23, 2021 - 8:12pm

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Kindbody , the leading fertility and family-building company seeking to revolutionize the patient experience, today announced the appointment of Dean Morbeck, Ph.D., as the Company's Chief Scientific Officer.

Key Points: 
  • NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Kindbody , the leading fertility and family-building company seeking to revolutionize the patient experience, today announced the appointment of Dean Morbeck, Ph.D., as the Company's Chief Scientific Officer.
  • "Dean has a wealth of experience in this field and is passionate about delivering the highest quality care to patients.
  • Under Dr. Morbeck's leadership, Kindbody will conduct research focused on making IVF more successful, ultimately leading to improved pregnancy rates.
  • Its leadership team includes President, Annbeth Eschbach; Chief Financial Officer, Meredith Whitney; Chief Medical Officer, Dr. Lynn Westphal; Chief Business and Legal Officer; Shilpa Patel; Founding Physician, Dr. Fahimeh Sasan; Chief Scientific Officer, Dean Morbeck; Chief Commercial Officer, Cindy Gentry; and Chief Technology Officer, Richard Forsythe.

Remote Medical Technologies Advances its Live-Dynamic Telepathology Solution with a NEW Gorgeous Local 4K Image Camera Package Offering for Multi-Headed Scope Rooms

Thursday, September 23, 2021 - 7:20pm

RMT's Telepathology Solution for Multi-Headed Microscopes comes equipped with a new and improved 4K camera designed and proven to progress operations.

Key Points: 
  • RMT's Telepathology Solution for Multi-Headed Microscopes comes equipped with a new and improved 4K camera designed and proven to progress operations.
  • The rmtConnect HTML5 Telepathology Solution is the stand-alone trailblazer for superior quality imaging with high performance and speed.
  • RMT has released a new rmtConnect package that offers a purpose-built solution that implements a new industry-leading live-dynamic local 4K video performance technology for immediate decision making.
  • NOTE: *Multi-headed scope room monitors must support 4:2:2 10 bit or 4:4:4 8 bit video formats for RMT Ikegami 4K camera operations.

 Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Thursday, September 23, 2021 - 4:31pm

Greater increases in HFMSE (non-ambulatory) and Revised Hammersmith Scale (ambulatory) scores were seen in patients who were not limited by scoliosis or joint contractures.

Key Points: 
  • Greater increases in HFMSE (non-ambulatory) and Revised Hammersmith Scale (ambulatory) scores were seen in patients who were not limited by scoliosis or joint contractures.
  • Virtual poster presentations (LBP.10 and EP.277) on September 23, 2021, at 16:30-18:30 BST
    E-Posters available to view on demand and exhibition area open starting Monday, September 20, 2021.
  • Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.
  • Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

CAP Advances Quality in Laboratory Medicine and Safeguards Patient Testing With Annual Release of Laboratory Accreditation Program Checklists

Thursday, September 23, 2021 - 12:00pm

The CMS regulates all laboratory testing, except research, performed on humans in the US through the Clinical Laboratory Improvement Amendments (CLIA).

Key Points: 
  • The CMS regulates all laboratory testing, except research, performed on humans in the US through the Clinical Laboratory Improvement Amendments (CLIA).
  • CAP members and affiliated experts scrutinize the checklists annually, working to integrate advancements in medicine, technology, and laboratory management, said Richard Scanlan, MD, FCAP, chair, CAP Council on Accreditation, which oversees the accreditation program.
  • For 75 years, the CAP has committed itself to providing programs for laboratories to achieve the highest standards for accurate patient testing.
  • The CAP will host a webinar, 2021 CAP Accreditation Checklist Updates: Changes that Matter , for laboratory professionals to review the updates.

Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease

Thursday, September 23, 2021 - 7:00am

Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.

Key Points: 
  • Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.
  • This knowledge is already fueling creation of novel prognostic tests for AD and may lead to the development of new therapies to counter disease progression."
  • p53 is involved in the regulation of oxidative stress, which is implicated as one of the earliest events in AD.
  • Diadem is preparing for rapid commercialization of its initial Alzheimer's prognostic via a global launch in collaboration with strategic partners.

Study Shows Heru’s Automated Visual Field Testing Platform Delivers Strong Correlation to Humphrey Field Analyzer

Wednesday, September 22, 2021 - 3:05pm

A report by Heru Inc. , the innovative vision diagnostics and augmentation leader, indicates that visual field test results from its wearable platform, re:Vive by Heru, are strongly correlated to the ZEISS Humphrey Field Analyzer (HFA).

Key Points: 
  • A report by Heru Inc. , the innovative vision diagnostics and augmentation leader, indicates that visual field test results from its wearable platform, re:Vive by Heru, are strongly correlated to the ZEISS Humphrey Field Analyzer (HFA).
  • (Graphic: Business Wire)
    Eye care professionals can trust the results of re:Vive by Heru for their patients, while capitalizing on the many advantages of our automated, time-saving visual field testing platform, said Mohamed Abou Shousha, M.D., Ph.D., CEO and founder, Heru.
  • Our patented re:Imagine threshold algorithm in the re:Vive platform shows a strong correlation with the Humphrey SITA Standard with excellent reproducibility, and a shorter testing time.
  • The study found strong correlations between Herus and HFAs visual field mean deviation and threshold values in normal eyes and eyes with glaucoma and other pathologies.

IV BioHoldings Debuts Liquid Biopsy Portfolio; Partners with P4 Diagnostix to Scale Commercialization of Non-Invasive Lung, Liver and Breast Diagnostics

Wednesday, September 22, 2021 - 4:14pm

Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.

Key Points: 
  • Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.
  • IVBH is now scaling to support its flagship lung, liver and breast programs through clinical development and commercialization.
  • We are a bio innovation studio specializing in de novo company creation at the intersection of diagnostics and life sciences.
  • P4 is made up of these industry-leading companies: Theranostix, Long Island Pathology, Platinum Pathology, Metamark Laboratories and P4 Clinical.

Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion

Wednesday, September 22, 2021 - 1:39pm

The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally.

Key Points: 
  • The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally.
  • Odysseys Phase 1 clinical trial status can be viewed at www.clinicaltrials.gov.
  • The most tolerated dose will be used in the subsequent trials to determine efficacy, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
  • Odyssey screening and enrollment of subjects coincides with the completion of their Phase 1 clinical batch of PRV-002.

Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer

Wednesday, September 22, 2021 - 1:02pm

Endeavor also announced today that Srikanth Pendyala, M.D., has been appointed as the companys first Chief Medical Officer.

Key Points: 
  • Endeavor also announced today that Srikanth Pendyala, M.D., has been appointed as the companys first Chief Medical Officer.
  • Hood added, We are also pleased to welcome Srikanth Pendyala as our chief medical officer.
  • Endeavors forward-thinking approach to precision therapies used to treat pulmonary disease and cancer has already exhibited immense potential since the company launched, said Srikanth Pendyala, M.D., Chief Medical Officer, Endeavor BioMedicines.
  • Endeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis.